MedTrace Logo

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

NCT01079819 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2011-02-07

No results posted yet for this study

Summary

The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of BMS-708163 administered as single and multiple doses in Chinese subjects

Conditions

Interventions

DRUG

BMS-708163

Capsule, Oral, 50 mg, once daily, 1 Day

DRUG

BMS-708163

Capsule, Oral, 125 mg, once daily, 14 Days

DRUG

Placebo

Capsule, Oral, 0 mg, One daily, 1 Day

DRUG

Placebo

Capsule, Oral, 0 mg, One daily, 14 Day

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079819 on ClinicalTrials.gov